Tissue Specific Gene Therapy for Human Prostate Cancer - Chinghai Kao

Abstract

Funding Agency

Agency: National Institute of Health (NIH)
Institute: National Cancer Institute (NCI)
Type: First Independent Research Support & Transition (FIRST) Awards (R29)
Project #: 5R29CA074042-04
Application #: 6173128
Study Section: Experimental Therapeutics Subcommittee 1 (ET)
Program Officer: Wolpert, Mary K

Project Start: 1997-04-01
Project End: 2000-05-31
Budget Start: 2000-04-01
Budget End: 2000-05-31
Support Year: 4
Fiscal Year: 2000
Total Cost: $18,057
Indirect Cost

Institution

Name: University of Virginia
Department: Urology
Type: Schools of Medicine
DUNS #: 001910777

City: Charlottesville
State: VA
Country: United States
Zip Code: 22904

Related projects


NIH 2001 R29 CA	Tissue Specific Gene Therapy for Human Prostate Cancer Kao, Chinghai / Indiana University-Purdue University at Indianapolis	$109,429
NIH 2000 R29 CA	Tissue Specific Gene Therapy for Human Prostate Cancer Kao, Chinghai / University of Virginia	$18,057
NIH 2000 R29 CA	Tissue Specific Gene Therapy for Human Prostate Cancer Kao, Chinghai / Indiana University-Purdue University at Indianapolis	$88,366
NIH 1999 R29 CA	Tissue Specific Gene Therapy for Human Prostate Cancer Kao, Chinghai / University of Virginia
NIH 1998 R29 CA	Tissue Specific Gene Therapy for Human Prostate Cancer Kao, Chinghai / University of Virginia
NIH 1997 R29 CA	Tissue Specific Gene Therapy for Human Prostate Cancer Kao, Chinghai / University of Virginia

Publications

Shirakawa, T; Gardner, T A; Ko, S C et al. (1999) Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol 162:949-54

Gotoh, A; Ko, S C; Shirakawa, T et al. (1998) Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 160:220-9

Comments

Be the first to comment on Chinghai Kao's grant